Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: ...

Key findings include: Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested. Precise MRD ...

The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN’s reach in MRD testing and cover solid tumors and hematological cancers. Minimal residual disease (MRD ...

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Adaptive Biotechnologies Corporation announced that its clonoSEQ® test for measurable residual disease (MRD) will be prominently featured in 30 presentations at the upcoming American Society of ...

FN America recently discovered a condition on the FN Reflex MRD pistol that, in very limited circumstances when using the incorrect set of screws to mount specific optics, the pistol could ...

The clonoSEQ test, which uses next-generation sequencing (NGS) for MRD assessment, will be included in studies presented both at the American Society of Clinical Oncology (ASCO) Annual Meeting ...

The data shows the prognostic value of Foresight CLARITY MRD detection at the end of frontline DLBCL in one of its largest prospective, real-world studies to date Data will be presented as an oral ...